In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
Figure 5
Influence on heart weight and tissue distribution of chiglitazar in rats. (a) Wistar rats were orally administered daily with chiglitazar at the dose of 15, 45 and 135 mg kg−1 for 6 months. 24 h after the last dosing, animals were sacrificed and the heart weight was evaluated. * compared with control; per group. (b) Male Wistar rats were orally administered with a single dose of 3H-chiglitazar at 12.5 mg kg−1 (radiation dose 31.7 MBq kg−1). Rats were sacrificed at 1.5, 4, 8, and 24 h after treatment ( per time point), and various tissues/organs as indicated were taken for radioactivity measurement. The accumulated area under curves through 0 to 24 h (AUC0–24) was calculated based on individual tissue distribution measured at each time point. (c) The time course distribution of chiglitazar in different tissues at individual time point (1.5, 4, 8, 24 h). Data are expressed as mean SE.
